Clinical Trials for Non-Small Cell Lung Cancer

A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves patients with metastatic or recurrent non-small cell lung cancer who have progressed after platinum-doublet chemotherapy and PD-1/PD-L1 blockade, testing a combination therapy of pembrolizumab (anti-PD-1), ramucirumab (anti-VEGF receptor), and docetaxel.

ClinicalTrials.gov ID: NCT04340882

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, PK and Anti-tumor Activity of YH42946 in Patients With Locally Advanced or Metastatic Solid Tumors With HER2 Aberration and EGFR Exon 20 Insertion

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients with advanced or metastatic solid tumors characterized by HER2 aberrations and EGFR exon 20 insertions and evaluates the safety and anti-tumor activity of YH42946, an oral tyrosine kinase inhibitor targeting HER2 mutations, particularly effective in NSCLC.

ClinicalTrials.gov ID: NCT06616766

A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients With Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial involves adult patients with advanced or metastatic solid tumors, including those with non-small cell lung cancer (NSCLC), breast, and colorectal cancer, particularly focusing on NSCLC with EGFR mutations during dose expansion, testing CPO301, an EGFR-targeting antibody-drug conjugate.

ClinicalTrials.gov ID: NCT05948865

Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates the safety and efficacy of PRO1184, a folate receptor alpha-targeted antibody-drug conjugate linked to exatecan, in patients with metastatic or unresectable solid tumors, including ovarian, endometrial, breast, non-small cell lung cancer, and mesothelioma, with specific cohorts for platinum-resistant ovarian cancer and combination therapies with carboplatin, bevacizumab, or pembrolizumab.

ClinicalTrials.gov ID: NCT05579366

A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC) receiving IOV-4001, a genetically modified tumor-infiltrating lymphocyte (TIL) therapy using TALEN® gene-editing to knock out PD-1, aiming to enhance TIL cells' efficacy against cancer.

ClinicalTrials.gov ID: NCT05361174

A Phase 1/2, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of JIN-A02 in Patients With EGFR Mutant Advanced Non-small Cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial targets patients with advanced NSCLC with EGFR mutations who have progressed after prior EGFR-TKI (including osimertinib) and/or platinum-based chemotherapy, assessing the safety and efficacy of JIN-A02, a fourth-generation EGFR tyrosine kinase inhibitor designed to overcome resistance related to EGFR mutations such as C797S.

ClinicalTrials.gov ID: NCT05394831

An Open-label Phase 1 Study to Investigate PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial is for adults with advanced metastatic or unresectable solid tumors, including colorectal, gastric, pancreatic, non-small cell lung, and small cell lung cancers, who have exhausted available treatments. It evaluates PF-08046050 (SGN-CEACAM5C), an antibody-drug conjugate targeting CEACAM5, utilizing a topoisomerase 1 inhibitor to induce cancer cell death.

ClinicalTrials.gov ID: NCT06131840

Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves patients with oligoprogressive non-small cell lung cancer who previously received first-line systemic therapies, evaluating the safety of adding the antimicrobial agent vancomycin to precision hypofractionated radiation therapy. Vancomycin, known for inhibiting bacterial cell wall synthesis, is used here to potentially reduce infections and modulate the immune response.

ClinicalTrials.gov ID: NCT03546829

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates SNS-101, a conditionally active anti-VISTA monoclonal antibody, as monotherapy and combined with cemiplimab (a PD-1 inhibitor) in patients with advanced solid tumors, including colorectal, head and neck, melanoma, and non-small cell lung cancers unresponsive to standard therapies.

ClinicalTrials.gov ID: NCT05864144

First-in-human Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Anti-CCR8 Antibody BAY 3375968 as Monotherapy and in Combination With Pembrolizumab in Participants With Selected Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial evaluates the safety and efficacy of the anti-CCR8 antibody BAY 3375968, which reduces regulatory T cells to boost immune response, as monotherapy and combined with Pembrolizumab in patients with advanced or metastatic solid tumors, including non-small cell lung cancer, triple-negative breast cancer, head and neck squamous cell carcinoma, and melanoma, particularly those unresponsive to current treatments.

ClinicalTrials.gov ID: NCT05537740